US EditionElinzanetant reduces vasomotor symptoms during breast cancer endocrine therapy
Summary by medwirenews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Elinzanetant reduces vasomotor symptoms during breast cancer endocrine therapy
By Lynda Williams, medwireNews ReportermedwireNews: The neurokinin-targeted agent elinzanetant significantly improves vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer, research indicates.This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.Read the full story on the L’Institut Servier websiteImage credit: © yacobchuk / Getty Images / iStock…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
